Chris Wright Touts Energy Department Report's Misleading Climate Claims
That's counter to authoritative climate science research. His statements come amid a push by the Trump administration to eliminate climate programs and scientist positions and to reduce access to past US-produced scientific reports, while issuing new material that goes against mainstream findings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
How to Watch the Northern Lights from These States Tonight
The aurora borealis will be visible from several U.S. states on Thursday, Aug. 7, and Friday, Aug. 8NEED TO KNOW The northern lights may be visible tonight across 18 U.S. states due to a G2-level geomagnetic storm Aurora activity is expected to peak overnight with potential viewing as early as this evening The Kp index is expected to rise, increasing the chances of northern lights farther south than usualGet ready for another round of auroras, stargazers! The cosmos is putting on a dazzling spectacle, as the northern lights make a rare appearance across parts of the U.S. starting as early as this evening. Auroras result from geomagnetic storms when charged particles from the sun collide with gases in the Earth's atmosphere. Their visibility depends on a number of factors, including intensity and location. According to NOAA's Space Weather Prediction Center (SWPC), space weather forecasters predict a chance of minor (G1) to moderate (G2) geomagnetic storms overnight with a slight chance of reaching strong (G3) levels. The stunning display is caused by solar particles interacting with Earth's magnetic field, and tonight's conditions are just right for the colors to be seen dancing across the sky — weather permitting. According to NOAA, auroras could begin appearing as early as 11:00 p.m. ET on Aug. 7 with moderate G2 geomagnetic storms between 2 a.m. and 5 a.m. ET, making tonight one of the best chances to catch a glimpse of the northern lights across parts of the northern states. Read on for how, when and where to look up and witness this celestial event. When will the northern lights be visible? Tonight, Aug. 7, into the early morning hours of Aug. 8 is your best viewing say auroras could begin as early as 11 p.m. ET tonight, with the strongest visibility expected between 2 a.m. and 5 a.m. on Aug. 8, but timing may vary depending on your location and local weather conditions. Where will the northern lights be visible? A G2-level geomagnetic storm means the northern lights could stretch much farther south than to forecasts from NOAA's Space Weather Prediction Center, visibility may extend across 18 U.S. states, including Montana, Alaska, North Dakota, Minnesota, Wisconsin, Michigan, Maine, South Dakota, Vermont, New Hampshire, Idaho, Washington, Oregon, New York, Wyoming, Iowa, Nebraska and best views will be in areas with dark skies and minimal light pollution, especially in rural or elevated spots facing north. How to watch the northern lights? To boost your chances, head outside around 2 a.m. and look toward the northern horizon. Find a location away from streetlights and city glare, whether it's a field, lakeside or a remote real-time aurora maps (like NOAA's Aurora Forecast tool) for updated activity. If the skies are clear and you're in the right region, you may catch glowing green, purple or red hues rippling across the stars. How to take photos of the northern lights? Great news! Even a smartphone can capture the auroras with a few tweaks: Use night mode or a long exposure setting. Stabilize your camera with a tripod or a steady surface. Turn off flash and manually adjust focus to infinity, if possible. Don't forget to turn your phone or camera toward the northern sky and take multiple exposures. Even if it looks faint to the eye, the camera may pick up more than you think. Read the original article on People
Geek Tyrant
26 minutes ago
- Geek Tyrant
James Cameron Warns That a Real-Life Terminator-Style AI Apocalypse Could Be Closer Than We Think — GeekTyrant
Filmmaker James Cameron might be harnessing artificial intelligence to revolutionize visual effects, but he's also raising alarms about where this tech could take us if paired with weapons. In a new interview with Rolling Stone, the Avatar and Titanic director shares his growing concern that the dark future he imagined in The Terminator isn't just sci-fi anymore. 'I do think there's still a danger of a Terminator' -style apocalypse where you put AI together with weapons systems, even up to the level of nuclear weapon systems, nuclear defense counterstrike, all that stuff,' Cameron said. 'Because the theater of operations is so rapid, the decision windows are so fast, it would take a super-intelligence to be able to process it, and maybe we'll be smart and keep a human in the loop. 'But humans are fallible, and there have been a lot of mistakes made that have put us right on the brink of international incidents that could have led to nuclear war. So I don't know.' Cameron sees us teetering on the edge of something big, saying: 'I feel like we're at this cusp in human development where you've got the three existential threats: climate and our overall degradation of the natural world, nuclear weapons, and super-intelligence,' he added. 'They're all sort of manifesting and peaking at the same time. Maybe the super-intelligence is the answer. I don't know. I'm not predicting that, but it might be.' The Terminator launched back in 1984 and imagined a grim future where an AI defense system called Skynet turns on humanity after becoming self-aware. With nuclear weapons and automated armies, it nearly wipes us out. It was sci-fi then, but Cameron believes we're edging closer to that reality. Despite his warnings, Cameron isn't writing off AI entirely. In fact, he's actively exploring how it can improve filmmaking. He joined the board of directors at Stability AI in 2024 and sees a future where AI dramatically speeds up production and cuts VFX costs without slashing jobs. 'If we want to continue to see the kinds of movies that I've always loved and that I like to make and that I will go to see — Dune, Dune: Part Two , or one of my films or big effects-heavy, CG-heavy films — we've got to figure out how to cut the cost in half,' he previosly explained. 'Now that's not about laying off half the staff and at the effects company. That's about doubling their speed to completion on a given shot, so your cadence is faster and your throughput cycle is faster, and artists get to move on and do other cool things and then other cool things, right? That's my sort of vision for that.' Still, when it comes to storytelling, Cameron isn't convinced AI can ever truly replace human creativity. In a previous interview, he shot down the idea of AI-written screenplays. 'I just don't personally believe that a disembodied mind that's just regurgitating what other embodied minds have said — about the life that they've had, about love, about lying, about fear, about mortality — and just put it all together into a word salad and then regurgitate it… 'I don't believe that's ever going to have something that's going to move an audience. You have to be human to write that. I don't know anyone that's even thinking about having AI write a screenplay.' So while Cameron is open to using AI as a creative tool, he's clearly drawing a line between innovation and annihilation. The tech might help make blockbusters more affordable, but if it finds its way into weapon systems, we could be headed straight into Terminator territory. Check out Rolling Stone to read Cameron's full interview and hear more of his thoughts on AI, filmmaking, and our uncertain future.
